Dr Eddy Stevens, CSO at Metrion, has over 25 years of experience in ion channel drug discovery. He is responsible for shaping the company's scientific strategy and ensuring the highest standards of scientific governance.

Before joining Metrion, Eddy served as CSO at Ario Pharma, where he led a TRPA1 discovery collaboration with a major global pharmaceutical company. Prior to that, he held several senior roles at Pfizer, including Head of Electrophysiology and a member of the Pain Research Unit Leadership Team at Pfizer Neusentis and Pfizer Sandwich. During his time there, he led multiple ion channel discovery programs, notably contributing to projects targeting Nav1.7 and Nav1.8.

Earlier in his career, Eddy was Chief Operating Officer at NeuroSolutions, a spin-out from the University of Warwick, and Head of the Ion Channel Group at Cambridge Drug Discovery/BioFocus, now part of Charles River Laboratories.

Eddy began his postdoctoral research at Parke-Davis UK, studying sodium channels in the context of pain mechanisms. He subsequently completed a postdoctoral fellowship at the University of Cambridge’s Department of Pharmacology, focusing on the molecular basis of Kir3 channel gating.

He holds a PhD from Imperial College London, where he characterised voltage-gated ion channels in epithelial cells, and a BSc (Hons) in Biology, also from Imperial College.

Over the course of his career, Eddy has authored 35 peer-reviewed publications and has contributed to the advancement of three compounds into clinical development, including playing a key role in the team that progressed the selective Nav1.7 inhibitor PF-05089771 to the clinic.